Period determination in the mammalian circadian clock involves the turnover rate of the repressors CRY and PER. We show that CRY ubiquitination engages two competing E3 ligase complexes that either lengthen or shorten circadian period in mice. Cloning of a short-period circadian mutant, Pasttime, revealed a glycine to glutamate missense mutation in Fbxl21, an F-box protein gene that is a paralog of Fbxl3 that targets the CRY proteins for degradation. While loss of function of FBXL3 leads to period lengthening, mutation of Fbxl21 causes period shortening. FBXL21 forms an SCF E3 ligase complex that slowly degrades CRY in the cytoplasm but antagonizes the stronger E3 ligase activity of FBXL3 in the nucleus. FBXL21 plays a dual role: protecting CRY from FBXL3 degradation in the nucleus and promoting CRY degradation within the cytoplasm. Thus, the balance and cellular compartmentalization of competing E3 ligases for CRY determine circadian period of the clock in mammals.
INTRODUCTION
In mammals, the circadian clock regulates daily oscillations in behavior, physiology, and metabolism (Bass and Takahashi, 2010; Mohawk et al., 2012) . The mechanism of the circadian clock is composed of an autoregulatory transcriptional network (Lowrey and Takahashi, 2011) . At the core, the transcription factors CLOCK and BMAL1 drive expression of the Period (Per) 1/2 and Cryptochrome (Cry) 1/2 genes. PER1/2 and CRY1/2 proteins in turn interact, translocate into the nucleus, and repress the activity of CLOCK:BMAL1 to inhibit their own transcription (King et al., 1997; Gekakis et al., 1998; Lee et al., 2001) . Bmal1 expression is also regulated by a secondary feedback loop comprised of the nuclear hormone receptors REVERBa/b and the retinoid-related orphan receptors (Preitner et al., 2002; Cho et al., 2012) .
Although the majority of the core clock components have been identified, the molecular mechanisms that define the periodicity or rate of the circadian clock are still not well understood (Zheng and Sehgal, 2012) . PER and CRY are essential negative feedback elements of the clock, and the turnover rates of PER and CRY are correlated with the period length of circadian rhythms in mutant strains. For example, the Casein kinase 1ε tau mutation shortens period and destabilizes the PER proteins by hyperphosphorylation of a phosphodegron site that targets the PER proteins for ubiquitination by b-TrCP and proteasomal degradation (Gallego and Virshup, 2007; Meng et al., 2008) . Conversely, mutations in the F-box protein FBXL3 lengthen period and stabilize the CRY proteins by a reduction in ubiquitination-mediated proteosomal degradation involving the SCF FBXL3 ubiquitin ligase complex Godinho et al., 2007; Siepka et al., 2007) . Recent work shows that CRY ubiquitination by SCF FBXL3 is triggered by AMPK-mediated phosphorylation (Lamia et al., 2009 ) and reversed by the deubiquitinating enzyme USP2a (Tong et al., 2012) . Genetic analysis of PER and CRY suggests that these two pathways act independently and additively to regulate circadian period in vivo (Maywood et al., 2011) . Here, we report the isolation and positional cloning of a circadian mutant, Past-time (Psttm) , that shortens circadian period and destabilizes CRY proteins during the circadian cycle. We describe an SCF ubiquitin ligase complex (SCF FBXL21 ) for the CRY proteins that plays a dual role to attenuate CRY degradation by SCF FBXL3 in the nucleus and to promote CRY degradation in the cytoplasm.
RESULTS

Identification of the Past-time mutation
In an ENU mutagenesis screen using C57BL/6J mice ( Figure S1 available online), we identified a short-period mutant with a period length of 22.91 hr (Figures 1A and 1B) . Crosses with C3H/HeJ mice produced animals of three phenotypic classes in the F2 generation, indicating that the mutant, named Past-time (Psttm), was semidominant ( Figure 1C ). We initially mapped the Psttm mutation to a 40 Mb region on chromosome 13 ( Figure 1D ). Production of additional recombinants further reduced the interval to 11.4 Mb. This smaller interval contains 167 open reading frames and no known circadian clock genes. However, one candidate, Fbxl21, is a paralog of FBXL3 and shares 85% amino acid sequence similarity (Jin et al., 2004) . FBXL3 has been shown to form a Skp1-Cul1-F-box protein (SCF) E3 ligase complex that polyubiquitinates the CRY proteins for degradation by the proteasome , and there is evidence suggesting that FBXL21 is a clock-controlled E3 ligase involved in ovine CRY1 degradation (Dardente et al., 2008) . We sequenced all of the exons of Fbxl21 from Psttm mice and found a single G-to-A change at nucleotide 787 in exon 5. This mutation cosegregated perfectly with the short-period phenotype of Psttm/ Psttm mice (0/156 recombinants; Figure 1D ). The point mutation converts amino acid 149 from a highly conserved glycine to a glutamic acid residue within the third leucine-rich repeat (LRR) of the protein. This G149E mutation is expected to create a charged protrusion, probably destabilizing the LRR structure ( Figure 1E ).
The Psttm Mutation Causes Period Shortening
To confirm that Fbxl21 is the causative gene, we generated transgenic mice expressing the Psttm allele using the The actogram is double plotted where each horizontal line represents 48 hr of activity. The mice were kept on an LD12:12 cycle (represented in the bar above) for the first 7 days and then released into constant darkness for 21 days (indicated by the arrowhead on the right). Actogram of the Past-time founder G3 mouse (period = 22.91 hr) (bottom). (C) Period distribution of F2 intercross mice used for genetic mapping. The three panels from top to bottom represent WT, Psttm/+, and Psttm/Psttm mice, respectively. ANOVA of the period was performed on the three populations of F2 mice (grouped by genotype) (DF = 2; F = 78.80; p = 3.983 3 10
À29
). (D) Psttm was initially mapped to a 40 Mb region on chromosome 13 between rs13481788 and rs367922 (left). The chromosome 13 schematic lists the markers used to map Psttm to a smaller genetic interval. Haplotypes of the 78 Psttm/Psttm F2 intercross progeny (156 meioses) are shown on the right. Black boxes represent C57BL/6J WT alleles, and white boxes represent C3H/HeJ alleles. The number of recombinants per total meioses is indicated to the right of the haplotype map. Sequencing of Fbxl21 where a single-base change from G to A is indicated by the asterisk (right). (E) Structural modeling of the FBXL21 LRR3 motif based on the Skp2 structure in WT and mutant proteins. See also Figure S1 . tetracycline-transactivator (tTA) system (Hong et al., 2007) . Three independent tetO::Psttm transgenic lines were crossed to Scg2::tTA mice in which the Secretogranin-2 promoter drives tTA expression in the SCN and other brain areas to evaluate whether the Psttm allele affects circadian behavior. Western blot analysis using cerebellum extracts confirmed that only double-transgenic mice showed mutant protein expression ( Figure S2A ). To determine whether Scg2::tTAdriven PSTTM expression in the brain also shortens freerunning period as seen in Psttm/+ mice ( Figure S2B ), we measured their circadian activity rhythms in constant darkness. Double-transgenic mice displayed short circadian periods compared with single-transgenic lines (Figures 2A and S2C ). The period shortening was conditional because doxycycline (Dox) treatment, which represses tTA transgene expression, restored the period to wild-type (WT) values (Figures 2A and S2C) . Removal of Dox from the drinking water after 4 weeks of treatment caused the double-transgenic mice to return to their previous, short free-running periods, confirming that inducible PSTTM expression was the cause of the short freerunning periods (Figures 2B and S2D) . In contrast, overexpression of WT FBXL21 under the control of the Scg2::tTA driver did not cause period changes in Scg2::tTA/tetO::Fbxl21 #38 mice (Figures S2E, S2F, and S2G) . Together, these observations show that conditional expression of the Psttm allele in the SCN and brain shortens circadian period in vivo, thus verifying that Fbxl21 is the causative gene. Because transgenic expression of Psttm in a WT background shortens period and because the Psttm allele is semidominant, this suggests that Psttm can act as an antimorphic mutation.
To investigate the effects of Psttm at the cellular and molecular level, we crossed the Psttm mice with mice carrying the Per2::luc reporter (Yoo et al., 2004) and examined the circadian rhythmicity in tissue explants from WT and Psttm homozygous mice ( Figure 2C ). SCN organotypic cultures from Psttm mice showed robust rhythms, yet with significantly shorter periods compared with those of WT SCNs ( Figure 2C , bottom right). Similarly, pituitary explants from Psttm mice also showed shorter periods than WT explants ( Figure 2C , bottom). Thus, the primary effect of the Psttm mutation on the circadian clock is period shortening at both behavioral and molecular levels.
The FBXL3 I364T mutation in Overtime (Ovtm) mutant mice lengthens period by about 2.5 hr, providing evidence that CRY stability is important for setting the pace of the clock (Siepka et al., 2007) . Given that both Ovtm and Psttm correspond to mutations in F-box genes related to CRY degradation, we created Psttm/Psttm Ovtm/Ovtm doublemutant mice to assess the genetic interaction of these mutant alleles ( Figures 2D and 2E ). While WT mice showed a mean period of 23.34 hr, Ovtm mice displayed a long period of 26.00 hr. In contrast, Psttm mice exhibited a short period of 22.77 hr. Interestingly, the Ovtm/Psttm double-homozygous mutant mice displayed a free-running period of 23.16 hr, similar to that of WT mice and different from the predicted value of 24.4 hr for an additive effect (Table S1 ). Thus, the Psttm and Ovtm alleles appear to act in an antagonistic rather than additive manner.
Effects of the Psttm Mutation on Core Clock Gene Expression
To explore the effects of the Psttm mutation on clock gene expression, we collected liver and cerebellum samples from WT and Psttm mice maintained in constant darkness and measured messenger RNA (mRNA) expression patterns. The Psttm mutation caused significant elevation of Per1, Per2, Cry1, and Cry2 transcripts in cerebellum and a moderate elevation of clock gene transcript levels in liver ( Figures 3A and S3A) , perhaps due to lower Fbxl21 expression in liver relative to cerebellum (mean Ct value of WT cerebellum and liver: 27.1 and 31.2, respectively; Figure S3D shows different levels of endogenous FBXL21 expression in various mouse tissues). Interestingly, the levels of several clock-controlled genes, including Rev-erba, Dec2, and Dbp, were significantly increased in liver ( Figure S3A ).
Next, we examined the effects of the Psttm mutation on core clock protein expression in cerebellum and liver. PER1 and PER2 levels were elevated in the cerebellum of Psttm mice (Figure 3B) , consistent with the observed increase in transcript levels. Furthermore, Psttm also appeared to advance the phase of the PER protein rhythm. In contrast, CRY1 protein levels were not elevated, and CRY2 levels were significantly reduced (Figure 3B) . Consistent with the previously reported rhythmic Fbxl21 mRNA accumulation (Dardente et al., 2008) , we observed a circadian oscillation of FBXL21 protein in the cerebellum of WT mice. In Psttm mutants, FBXL21 protein levels in cerebellum were significantly reduced throughout the circadian cycle compared with WT ( Figure 3B ), suggesting the Psttm mutation impaired FBXL21 protein stability. In addition, in the liver of Psttm mutants, the phase of PER1/2 and CRY1/2 accumulation was advanced relative to WT ( Figure 3C ). FBXL21 protein accumulation was also both reduced and phase advanced in Psttm liver. The reduction in CRY, despite enhanced transcript levels, suggests that the Psttm mutation leads to the destabilization of CRY protein. In addition, because the expression of FBXL21 is rhythmic and in phase with that of CRY1/2 ( Figure 3B ), it is possible that FBXL21 could exert phase-dependent effects.
To determine whether the Psttm mutation affects CRY expression in the SCN, we used immunocytochemical quantitation of SCN sections from WT and Psttm mice. As shown in Figure 3D , the number of CRY1-positive nuclei was significantly reduced in SCN from Psttm mice at ZT0, 8, and 12 compared with WT controls ( Figures 3E, S3B , and S3C). Taken together, these experiments show that the Psttm mutation leads to a general increase in the RNA expression of CLOCK:BMAL1 target genes, while at the same time altering the expression of CRY1 and CRY2 proteins and substantially reducing FBXL21 protein levels. The reduction in CRY, despite enhanced transcript levels, suggests that the Psttm mutation leads to destabilization of CRY protein.
FBXL21 Stabilizes CRY by Competing against FBXL3
The concomitant reduction of FBXL21 and CRY proteins caused by the Psttm mutation prompted us to investigate the biochemical interaction between CRY and FBXL21. Coimmunoprecipitation (co-IP) assays showed that among the six core clock proteins in the primary loop (CRY1/2, PER1/2, CLOCK, BMAL1), only CRY1 and CRY2 were able to interact with both FBXL21 and PSTTM ( Figure S4A ). All CRY1 mutants with C-terminal domain truncation were coimmunoprecipitated with both FBXL3 and FBXL21, indicating that FBXL binds to CRY in the photolyase homology domain of CRY1 (amino acids 1-530) ( Figure S4 ). Next we expressed the F-box proteins in NIH 3T3 cells and the cell lysates were immunoprecipitated with anti-FLAG (FBXL3, FBXL21, PSTTM) or anti-V5 (b-TrCP1) antibodies. All the F-box proteins, including PSTTM, were found to interact strongly with native CULLIN1 and SKP1 (the other components of the SCF complex), indicating that FBXL21 and PSTTM can form SCF E3 ligase complexes ( Figure 4A ). Only low levels of Figure 1B . (E) Period distribution. The four panels from top to bottom represent WT, Ovtm/Ovtm, Psstm/Psstm, and Ovtm/Ovtm Psttm/Psttm mice, respectively. ANOVA of the period was performed among the genotype groups. Results: DF = 3; F = 388.507; p = 2.295 3 10 À51 . See also Figure S2 and Table S1 .
CRY1 coimmunoprecipitated with ectopically expressed FBXL3, probably due to robust CRY1 degradation. To our surprise, FBXL21 or PSTTM coimmunoprecipitated much higher levels of CRY1 compared with FBXL3. The stable binding between CRY1 and FBXL21/PSTTM differs from the transient E3 ligasesubstrate interaction commonly associated with rapid degradation seen with FBXL3-CRY. In addition, ectopically expressed PSTTM and FBXL21 both showed strong affinity toward CRY, indicating that the mutation does not significantly affect CRY binding.
To verify the interactions between FBXL21 and CRY1/2 in vivo, we assessed native protein interactions over the circadian cycle by immunoprecipitating endogenous FBXL21 proteins from WT and Psttm liver tissue lysates collected at different circadian times ( Figures 4B and 4C ). Levels of coimmunoprecipitated CRY1/2 showed a circadian rhythm correlated with their periodic accumulation ( Figure 3C ) in WT tissue; on the other hand, lower levels of CRY1/2 were pulled down in Psttm liver, presumably due to reduced FBXL21 expression ( Figure 3C ). Next, we compared the potential E3 ligase activity of FBXL3 with that of FBXL21 and PSTTM in CRY-degradation assays in 293A cells ( Figures 4D, S4B , and S4C). In the absence of ectopic FBXL3 expression, transfected CRY1 had a half-life of 2.1 hr ( Figure 4D and Figure S4C for CRY2). This rapid degradation was reversed when Cry1 was cotransfected with hFbxl3si RNA, indicating that endogenous hFBXL3 regulates CRY1-HA degradation in 293A cells ( Figure S4D ). As expected, cotransfection of FBXL3 accelerated CRY1 degradation (0.75 hr). In contrast, cotransfection of FBXL21 significantly decelerated CRY1 degradation (12.3 hr). PSTTM also appeared to slow down CRY1 degradation, but to a lesser extent than WT FBXL21 (3.7 hr). Because endogenous hFBXL3 is present, exogenously expressed FBXL21 probably antagonizes endogenous hFBXL3 to reduce CRY1 degradation. Since FBXL21 is a less efficient E3 ligase for CRY1 than FBXL3 ( Figure 4D ), FBXL21 can act antagonistically with FBXL3. In addition, because PSTTM itself is less stable than WT FBXL21 (Figure 4E) , PSTTM (4 hr) would be expected to antagonize SCF FBXL3 less efficiently than WT FBXL21 (8.6 hr). Next we introduced the corresponding Psttm mutation into Fbxl3 (G143E) and measured the effect of the mutation on CRY1 degradation and FBXL3 stability ( Figure S4B , bottom). The G143E mutation in Fbxl3 did not alter protein stability or E3 ligase activity of FBXL3. Importantly, we rule out the possibility of FBXL21 or PSTTM as an E3 ligase for FBXL3: coexpression of FBXL21 or PSTTM showed no effects on FBXL3 stability independent of CRY, indicating that FBXL21 does not decelerate CRY degradation by serving as an E3 ligase for FBXL3 ( Figure S4E ).
To test the hypothesis that FBXL21 antagonizes FBXL3, we performed competition assays for CRY1 degradation in 293A cells (Figures 4F and S4F) . In support of an antagonistic relationship, coexpression of FBXL3 and FBXL21 resulted in an intermediate CRY1 half-life (4.4 hr) relative to expression of CRY1 with either FBXL3 (1.9 hr) or FBXL21 alone (11 hr). Interestingly, in the presence of FBXL3, PSTTM was less effective in decelerating CRY1 degradation (3 hr) than FBXL21 (4.4 hr). This supports the conclusion that PSSTM is a less effective antagonist of FBXL3-mediated CRY degradation than WT FBXL21. Next, we carried out similar assays using the hypomorphic Ovtm mutant of Fbxl3 to investigate whether the WT-like circadian periodicity in Ovtm/Psttm compound homozygous mice is associated with restored CRY degradation rate (Figures 2D and 2E) . Specifically, 293A cells were cotransfected with Cry1 and F-box pairs, Ovtm+Fbxl21, and Ovtm+Psttm. CRY1 degradation was attenuated in the presence of OVTM (4.9 hr; Figures 4F, bottom, and S4G), whereas PSTTM expression in place of FBXL21 restored CRY1 degradation in the presence of OVTM (1.6 hr). These changes in CRY1 degradation rate are directly correlated with the period shortening or lengthening in the Psttm and Ovtm mouse mutants ( Figure 2E ), suggesting that the WT periods of Ovtm/Psttm mice resulted from an antagonistic interaction of the two mutations on CRY degradation, in which impaired CRY degradation in OVTM was rescued in the presence of PSTTM.
To verify definitively that FBXL21 forms an SCF E3 ligase complex, we performed in vitro ubiquitination assays to examine the ubiquitination activity of SCF FBXL3 , SCF
FBXL21
, and SCF PSTTM . CRY1 was efficiently polyubiquitinated in the presence of SCF FBXL3 complex. Both FBXL21 and PSTTM were able to carry out CRY1 polyubiquitination but were less active in generating highly polyubiquitinated forms of CRY compared with FBXL3 ( Figure 4G , bottom: long exposure). The observed differences in CRY ubiquitination processivity by FBXLs paralleled their effects on CRY degradation ( Figure 4D ). CRY1 ubiquitination by SCF FBXL3 was significantly reduced in the presence of SCF FBXL21 or SCF PSTTM ( Figure 4H ), suggesting that attenuated CRY1 degradation in the presence of both FBXL3 and FBXL21 ( Figure 4F , top) was due to direct competition between FBXL3 and FBXL21 as CRY1 E3 ligases ( Figure 4H ). As shown in the end-point competition assay ( Figure S4H ), FBXL21 and PSTTM (to a lesser extent than WT) were able to protect CRY1 from FBXL3-mediated degradation in a dose-dependent manner, suggesting direct competition between FBXL3 and FBXL21.
No activity was detected from in vitro ubiquitination assays using the UBC13/Uev1A E2 ligase required for K63 ubiquitination ( Figure 4I ), indicating that FBXL21 is not involved in nonproteolytic K63 ubiquitination and that CRY stabilization ( Figure 4D ) does not involve K63 ubiquitination by FBXL21. To confirm these results in intact cells, we performed ubiquitination assays by expressing CRY1, the F-box proteins, and ubiquitin (hUb) in 293A cells in the presence of the proteasome inhibitor MG132 ( Figure 4J ). Consistent with the in vitro assay results, FBXL21 and PSTTM showed significantly attenuated polyubiquitination activity relative to FBXL3.
Psttm and Fbxl21 Knockdown Differentially Alter Nuclear and Cytoplasmic CRY Degradation To determine the allelic nature of the Psttm mutant, we compared the effects of the Psttm mutation with loss of function of Fbxl21 using small hairpin RNA (shRNA) knockdown of Fbxl21 (shFbxl21) on mPER2::LUC rhythms in mouse embryonic fibroblasts (MEFs). Psttm MEFs showed advanced phases with significantly shorter periods relative to WT MEFs ( Figures 5A  and 5D ). PSTTM was less abundant than WT FBXL21 in MEFs from the mPER2::LUC genetic background ( Figure 5C, left) , consistent with what we observed in the tissue samples ( Figures  3B and 5C ), and knockdown efficiently depleted FBXL21 protein ( Figure 5C , right). Importantly, Fbxl21 knockdown also elicited phase-advance and period-shortening phenotypes compared with shRNA control MEFs ( Figures 5B and 5D ), indicating that the Psttm allele behaves as either a loss-of-function hypomorphic allele or a dominant-negative antimorphic allele. This is consistent with the in vitro ubiquitination assays that show that SCF Psttm also does not show a significant gain of function in ubiquitination activity relative to SCF FBXL21 . To investigate the cellular localization of Fbxl21 and Psttm action on CRY abundance, we prepared nuclear and cytoplasmic fractions from samples collected over the circadian cycle and assessed CRY levels ( Figures 5E, 5F , S5A, and S5B). In Psttm MEFs, nuclear CRY1 and CRY2 levels were significantly lower than in WT (Figures 5E, top right, and CRY2 results are shown in Figure S5A ). In contrast, cytoplasmic CRY levels were significantly elevated in Psttm MEFs throughout the cycle ( Figure 5E , bottom right, and Figure S5A ). In a similar manner, Fbxl21 knockdown reduced nuclear CRY1/2 ( Figure 5F , top right, and Figure S5B ) compared to GFP control yet enhanced cytoplasmic CRY1/2 levels ( Figure 5F , bottom right, and Figure S5B) . To understand the mechanism underlying the differential effects of FBXL21/PSTTM on nuclear and cytoplasmic CRY levels, we compared the rate of CRY degradation in nuclear and cytoplasmic fractions from WT versus Psttm MEFs and shControl versus shFbxl21 cell lines ( Figures 5G and 5H ). Both the Psttm mutation and Fbxl21 knockdown accelerated nuclear CRY1/2 degradation compared with controls ( Figures 5G and  5H) , with opposite effects on cytoplasmic CRY degradation. Endogenous FBXL21 was detected in both nuclear and cytoplasmic fractions, and the Psttm mutation impaired FBXL21 accumulation in both subcellular compartments ( Figure 5G ). Neither the Psttm mutation nor depletion of endogenous FBXL21 had any effect on nuclear FBXL3 protein levels (Figure S5C) . Together, these findings demonstrate that reduced levels of FBXL21 elicited opposing effects on CRY degradation in the nucleus and the cytoplasm, leading to CRY accumulation in the cytoplasm but accelerated turnover in the nucleus.
FBXL21 Forms SCF Complexes in the Cytoplasm
To determine the subcellular localization of the FBXL proteins, we generated fluorescent protein fusions of the FBXL proteins. Consistent with previous results (Cenciarelli et al., 1999) , Venus-FBXL3 localized primarily to the nucleus ( Figure 6A ). On the other hand, Venus-FBXL21 was found in both the nucleus and the cytoplasm ( Figure 6A ), in accordance with MEF-fractionation experiments ( Figure 5G ). Venus-PSTTM showed a subcellular distribution similar to WT FBXL21, and Venus-CRY1 localized primarily in the nucleus as reported previously (Yagita et al., 2002) . Next we used bimolecular fluorescence complementation (BiFC) to investigate the subcellular localization of FBXL-CRY1 complexes. Specifically, CRY1-VenC was coexpressed with the indicated VenN-FBXLs ( Figure 6B ), and protein interaction was measured at the Venus emission wavelength (528 nm). The CRY1-FBXL3 complex was observed primarily in the nucleus ($90%), whereas CRY1-FBXL21 or CRY1-PSTTM complexes were found in both the nucleus and cytoplasm. Furthermore, a three-way competitive BiFC assay (Kerppola, 2006) , in which C-terminal Cerulean fused to CRY1 (CRY1-CerC) was allowed to interact with FBXL proteins fused with either Ven-N (VenN-FBXLs) or Cer-N (CerN-FBXLs), demonstrated that FBXL21, and to a lesser degree PSTTM, interact with CRY1 more strongly than FBXL3 ( Figure 6C , bottom: quantification).
To investigate the cause of the differential effects of FBXL21 depletion on subcellular CRY degradation, we examined SCF complex formation involving FBXL3, FBXL21, and PSTTM by using BiFC assays. Ven-C and Ven-N were fused to the N termini of CULLIN1 or SKP1 and the N termini of FBXL3, FBXL2,1, or PSTTM, respectively. SKP1-FBXL3 and CULLIN1-FBXL3 complexes were observed primarily in the nucleus ( Figure 6D ). In contrast, SKP1-FBXL21, SKP1-PSTTM, CULLIN1-FBXL21, and CULLIN1-PSTTM complexes were abundant in the cytoplasm ( Figures 6D and 6E) . Together, these results demonstrate that FBXL21 is primarily involved in CRY degradation in the cytoplasm and that the unstable Psttm allele or Fbxl21 knockdown leads to cytoplasmic CRY accumulation. On the other hand, reduced nuclear FBXL21 levels in Psttm or Fbxl21 knockdown MEFs reduce the antagonistic effects of FBXL21 against FBXL3, leading to accelerated CRY degradation in the nucleus.
FBXL3 and FBXL21 Ubiquitinate Distinct Lysine
Residues to Regulate CRY1 Degradation In order to delineate the mechanism of CRY1 degradation by FBXL3 and FBXL21, we sought to identify the ubiquitination sites required for CRY1 degradation by these two F-box proteins. Initially we chose 18 conserved lysine residues in CRY1 and CRY2 and converted them individually to arginine to test for loss of function. No single lysine residue was found to be critically required for CRY1 degradation in the presence of FBXL3 or FBXL21. Of these individual CRY1 mutants, K107R and K228R showed mildly impaired degradation by FBXL3. Although K159R and K308R are not conserved between CRY1 and CRY2, these sites showed similarity to the consensus sequence of ubiquitination sites (Catic et al., 2004) , and the K159R/K308R double mutation caused mild CRY1 stabilization. These initial experiments suggested that multiple lysine residues probably play redundant roles for CRY1 degradation. Thus we also employed a reverse approach, starting from a degradation-resistant mutant CRY1, in which all 31 lysine residues were mutated to arginine (CRY1:R). To determine whether CRY1:R retained protein-protein interactions comparable to WT CRY1, we first performed coimmunoprecipitation with FBXL3 and FBXL21. As shown in Figure 7A , cotransfected FBXL3 immunoprecipitated low levels of WT CRY1-HA in the absence of MG132, probably due to active CRY1 degradation. In contrast, CRY1:R efficiently coimmunoprecipitated with FBXL3; concordantly, the in vivo ubiquitination assay showed that this mutant was resistant to FBXL3-mediated ubiquitination ( Figure 7A, right) . Furthermore, co-IP with PER2 confirmed that CRY1:R could also interact with PER2 ( Figure 7A , bottom). In addition, reporter assays using a mPer2 promoter construct, pGL6 (Yoo et al., 2005) , demonstrated that CRY1:R was able to repress CLOCK:BMAL1 transactivation of E-box-dependent transcription to a similar extent as WT CRY1 ( Figure 7B ). Thus, mutation of all 31 lysine residues in CRY1 renders it resistant to ubiquitination and degradation but surprisingly functional in protein interaction and transcriptional repression assays. We then used site-directed mutagenesis to generate 31 individual lysine revertants from Cry1:R to test for gain of function. Individual clones were transfected, either alone or cotransfected with Fbxl3 or Fbxl21 expression constructs, into 293A cells, and degradation was monitored as above ( Figures S6 and S7 ). An initial gain-of-function screen revealed six putative FBXL3 target residues: K68, K189, K277, K456, K585, and K599 ( Figure 7F ). Combining the four aforementioned residues from the initial loss-of-function screen, we generated a panel of ten candidate lysine revertants from Cry1:R, and degradation of these mutants in the presence of FBXL3 and FBXL21 is shown in Figure 7C . We further divided the candidate lysine sites into two groups according to their proximity to known CRY1 phosphorylation sites (Lamia et al., 2009) . Cry1:R-6Ks is a six-lysine revertant where the lysine residues are located close to phosphorylation sites, whereas Cry1:R-4Ks contains four lysine residues without nearby phosphorylation sites. As shown in Figure 7C , CRY1-10K regained FBXL3-mediated degradation, displaying a degradation rate similar to that of WT CRY1 ( Figure 7D ). Interestingly, Cry1:R-6Ks displayed a similar degradation rate as Cry1:R-10K, whereas Cry1:R-4Ks was much more stable. Multiple CRY1 mutants with fewer lysine combinations were more resistant to FBXL3-mediated degradation than Cry1:R-6Ks. Thus, there are multiple and redundant potential CRY1 degron sites for FBXL3. FBXL21 expression showed no effects on the half-life of these revertant CRYs, indicating that FBXL3 and FBXL21 do not share ubiquitination sites. Remarkably, similar site mapping for FBXL21 revealed a single candidate residue, K11 (Figure 7E ), as the preferred ubiquitination site for FBXL21 ( Figure S7) . Figure 7F shows a summary of results from degron screening. As indicated by the green boxes, FBXL3 appears to utilize multiple lysine residues for CRY1 degradation. In contrast, FBXL21 showed a highly restricted preference for CRY1 ubiquitination, perhaps explaining why FBXL21 displayed low activity in CRY degradation.
DISCUSSION
CRY proteins are the major negative regulators in the core loop of the mammalian circadian clock. Multiple lines of evidence suggest a key role for CRY1 in regulating circadian period length. For example, impaired CRY degradation in the Ovtm mutant caused significant repression of CLOCK:BMAL1-driven transcription and lengthening of period (Siepka et al., 2007) . In addition, it has been known for more than a decade that the Cry1 knockout mouse has a short period while the Cry2 knockout has a long period (van der Horst et al., 1999; Vitaterna et al., 1999) . Recent work has provided insight into the transcriptional regulation of Cry1 (Ukai-Tadenuma et al., 2011) , as well as CRY2 amounts. Error bars represent mean ± range (n = 2 experiments). Two-way ANOVA shows statistically significant differences between WT and Psttm for the amount of CRY1 coprecipitated with FBXL21 throughout the circadian cycle (p < 0.0001). (D) Differential effects of FBXL21 and PSTTM on CRY1 stability. 293A cells were cotransfected with indicated constructs. Thirty-two hours after transfection, cells were treated with 20 mg/ml cycloheximide and incubated for the indicated time before harvest. Western blotting was performed to monitor CRY1 levels using an anti-HA antibody. Bottom: quantification of the effects of FBXL3, FBXL21, and PSTTM on CRY1 stability. Error bars represent mean ± SEM (n = 3 experiments). Half-life was determined by using nonlinear, one-phase exponential decay analysis (half-life parameter, K, is significantly different in all four conditions: p < 0.0001). 
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Relative abundance identification of a domain in CRY1 that is required for the maintenance of circadian rhythms (Khan et al., 2012) . Despite these advances, how CRY stability and turnover are regulated and how CRY stability is related to circadian period remains to be understood. Here, we identified a short-period mutant, Past-time, that is caused by a G149E missense mutation in FBXL21, a leucine-rich repeat F-box protein that is a paralog of FBXL3, an E3 ligase responsible for CRY protein turnover. Contrary to working in an additive manner with FBXL3, as might be expected of a paralog, we find instead that FBXL21 antagonizes FBXL3 in genetic interaction experiments in vivo, in cellular assays of CRY stability, and in biochemical ubiquitination assays of the reconstituted SCF E3 ligase complex in vitro. Taken together, these experiments show definitively that FBXL21 interacts with FBXL3 to counterbalance the E3 ligase activity of SCF FBXL3 on CRY1 and CRY2 to stabilize them, consistent with the accompanying paper by Hirano et al. (2013) (Reed, 2003; Pines, 2011) . For example, turnover of the key cell-cycle regulator MYC has been shown to be regulated by distinct E3 ligases, such as SCF FBW7 , SCF SKP2 , and SCF bTrCP , at various cell-cycle phases (Popov et al., 2010) . Additionally, p53 protein degradation also appears to involve several E3 ligases including Mdm2, ARF-BP1, PIRH2, COP1, and WWP1 (Dai and Gu, 2010) . Importantly, SCF bTrCP and WWP1 have been shown to confer substrateprotective functions for MYC and p53, respectively. However, unlike any of these precedents for interacting E3 ligases in the cell cycle, where distinct E3 ligases from different protein families interact, the antagonism of two paralogous SCF complexes (SCF FBXL3 and SCF FBXL21 ) in the same pathway is unique. . Statistically significant difference in period was detected between WT (24.4 hr, n = 6) and Psttm (23.1 hr, n = 6) MEFs (t test: *p < 0.001,). Likewise, statistically significant difference in period was detected between Lenti-GFP (24.06 hr, n = 6) and LentiFbxl21si (22.68 hr, n = 6) MEFs (t test: *p < 0.001). Error bars represent mean ± SEM. (E) The Psttm mutation decreases nuclear CRY1 levels and oscillation amplitude. Western blotting for CRY1 was performed using nuclear and cytosolic fractions. Right: quantification from triplicates including examples shown here. CRY1 levels from Psttm nuclei were significantly reduced (top, two-way ANOVA, p < 0.001) relative to CRY1 from WT nuclei. In contrast, cytoplasmic CRY1 levels from Psttm were significantly elevated throughout the circadian cycle (bottom, two-way ANOVA, p < 0.001). Error bars represent mean ± SEM (n = 3). (F) Fbxl21 depletion reveals that Psttm behaves as either a loss-of-function or a dominant-negative mutation relative to WT Fbxl21. Lenti-GFP-and LentiFbxl21sh-infected mPER2::LUC MEFs were treated the same as in (E) . Right: quantification from triplicates including example shown in (F) . Error bars represent mean ± SEM (n = 3). CRY1 levels in Lenti-Fbxl21sh nuclei were significantly reduced (p < 0.001), whereas cytoplasmic CRY1 levels were significantly increased throughout the circadian cycle (p < 0.001).
(G) Accelerated nuclear CRY degradation and decelerated cytoplasmic CRY degradation in Psttm and Fbxl21 knockdown MEFs. Western blotting was performed using anti-CRY1, -CRY2, and -FBXL21 antibodies for nuclear and cytoplasmic fractions. Representative blots from three experiments are shown.
(H) Quantification of nuclear and cytoplasmic CRY1 and CRY2 degradation in Psttm and Fbxl21sh MEFs from triplicate experiments including the representative blots shown in (G) . Error bars represent mean ± SEM (n = 3). See also Figure S5 .
Translocation between the cytoplasm and the nucleus is a key step in the circadian cycles of both the positive factors (CLOCK: BMAL1) (Kondratov et al., 2003) and the negative factors (CRY/ PER) of the core circadian loop. The subcellular distribution and relative E3 ligase activity of FBXL3 and FBXL21 create a regulatory mode for CRY stability in the cell, analogous to that seen in the cell cycle where the ubiquitin-proteasomal system can degrade a specific protein at a specific time and in a specific place (Pines and Lindon, 2005) . Thus, the discovery of FBXL21 and the differential regulation of CRY stability in the nucleus and cytoplasm reveal a prominent and sensitive role of the nucleus in regulating circadian period.
EXPERIMENTAL PROCEDURES
ENU Mutagenesis Screen and Characterization of Psttm Phenotypes ENU mutagenesis screen for circadian mutants, genetic mapping, and positional cloning was performed as described previously (Siepka et al., 2007) . Confirmation of the mutant gene by transgenic expression of the mutant Psttm allele, Per2::luciferase bioluminescence recording, genetic interaction (legend continued on next page) experiments, and circadian gene expression analysis are described in the Extended Experimental Procedures. All animal care and experimental treatments were in accordance with Northwestern University and UT Southwestern Medical Center guidelines for animal care and use.
CRY Degradation, In Vitro Ubiquitination Assays, and Subcellular Localization The interaction of FBXL proteins with CRY1/2, and the effects of FBXL proteins on CRY degradation rates were performed as described (Siepka et al., 2007) . CRY1-containing SCF complexes were purified from Sf9 cells (Invitrogen) using M2 FLAG agarose. Ubiquitination assays for CRY1 were carried out as described previously (Xu et al., 2009) . CRY interaction and degradation assays were also performed on nuclear and cytoplasmic fractions. BiFC assays were performed as described (Kerppola, 2006) .
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven figures, and two tables and can be found with this article online at http://dx.doi. org/10.1016/j.cell.2013.01.055.
